FDA finds deficiencies in Mylan's generic Advair

(Reuters) - U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.

Read more...
Positive 0 LOL 0 Interesting 0 Sad 0 Revolting 0 Fake 0

Whoops, looks like something went wrong.